- Home
- AAMI vs PRCT Comparison
AAMI vs PRCT Comparison
Compare AAMI & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AAMI | PRCT |
|---|---|---|
| Founded | 1980 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | AAMI | PRCT |
|---|---|---|
| Price | $55.61 | $30.73 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $48.67 | ★ $51.13 |
| AVG Volume (30 Days) | 186.2K | ★ 1.0M |
| Earning Date | 02-05-2026 | 02-24-2026 |
| Dividend Yield | ★ 0.07% | N/A |
| EPS Growth | ★ 45.00 | N/A |
| EPS | ★ 2.40 | N/A |
| Revenue | ★ $559,300,000.00 | $299,907,000.00 |
| Revenue This Year | $17.23 | $48.30 |
| Revenue Next Year | $24.02 | $29.44 |
| P/E Ratio | $22.91 | ★ N/A |
| Revenue Growth | 19.25 | ★ 50.07 |
| 52 Week Low | $22.60 | $27.80 |
| 52 Week High | $55.38 | $76.95 |
Technical Indicators
Market Signals| Indicator | AAMI | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 75.56 | 43.31 |
| Support Level | $52.00 | $29.65 |
| Resistance Level | $55.10 | $31.26 |
| Average True Range (ATR) | 1.99 | 1.73 |
| MACD | 0.44 | -0.21 |
| Stochastic Oscillator | 92.66 | 18.94 |
Price Performance
Historical ComparisonAbout AAMI Acadian Asset Management Inc.
Acadian Asset Management Inc is a holding company that operates a systematic investment management business through its subsidiary, that offers institutional investors across the globe access to a diversified array of systematic investment strategies designed to meet a range of risk and return objectives.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.